CRUK, MedImmune ally on cancer biologics

Cancer Research UK and the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said they will establish the joint CRUK-MEDI Alliance Laboratory in Cambridge, U.K. The five-year public-private partnership will seek to develop biologic cancer treatments.

MedImmune will contribute a laboratory head and another full-time employee, as well as its phage display technology and development expertise. Cancer Research UK will provide facilities and equipment along with a portfolio of drug targets and a scientific team. The joint research projects have not yet been determined. ...